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Why was the Consortium set up?
Epigenetics refers to mitotically heritable changes to the
DNA, which do not affect the DNA sequence, but can influ-
ence its function. Currently, DNA methylation is the most
studied epigenetic phenomenon in large populations. It entails
the binding of a methyl group, mainly to positions in genomic
DNA where a cytosine is located next to a guanine, a
cytosine-phosphate-guanine (CpG) site (Figure 1). DNA
methylation at CpG sites can influence gene expression by
altering the DNA’s three-dimensional structure and interact-
ing with methyl-binding proteins, consequently affecting the
binding of the gene transcription and chromatin-modifying
machinery. There are approximately 28 million CpG sites in
the human genome. DNA methylation is a dynamic process
that can be influenced by genetic factors, as well as by envir-
onmental factors such as diet, air pollution, toxicants or
smoking.1–4 Hence, DNA methylation may be seen as linking
the genome to the environment with respect to health and dis-
ease. Early development is a period of profound changes in
DNA methylation and may, as such, be a critical period for
environmentally-induced DNA methylation changes.4 Hence,
this period is of specific interest for DNA methylation studies
in relation to specific exposures and long-term health out-
comes.1,4–6
Figure 1. Schematic representation of DNA methylation. The figure
shows a double DNA strand on the top right, with CpG sites which are
methylated by the addition of a methyl group (M). DNA is transcribed
into messenger RNA (mRNA). DNA methylation can influence transcrip-
tion either positively or negatively, depending on the location of the
methylated site. After transcription, mRNA is translated into proteins.
Adapted with permission from Felix JF et al.64
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DNA methylation modifications in early life represent
an important potential mechanism for studies on the devel-
opmental origins of health and disease (DOHaD). The
DOHaD hypothesis suggests that exposure to an adverse
environment in fetal life or early childhood leads to per-
manent changes in organ structure or function, which may
have effects on later life health.7,8 Many associations of
early life adverse exposures, such as maternal obesity,
smoking, air pollution and suboptimal diet, with common
diseases throughout the life course have been described.9–12
Long-lasting DNA methylation modifications may be an
important mechanism linking early life exposures with out-
comes in later life.13 Besides having a potential mechanistic
role, DNA methylation may also serve as a biomarker of
exposures or outcomes, even without it having a direct
causal role in the process.3,14,15 For example, an environ-
mental factor may cause both a change in phenotype and a
change in DNA methylation, without a causal relation be-
tween the two. Also, a disease could cause a change in
DNA methylation, rather than the other way around.15 The
ability of methylation signals to serve as strong biomarkers
of some exposures, such as maternal smoking in pregnancy,
may complicate inference about the role in mediating health
outcomes; measurement error correction may help in this
regard.16 Various pregnancy, birth and childhood studies
have recently initiated research on the role of DNA methy-
lation in the response to environmental exposures and de-
velopment of health outcomes. Individual studies usually
have sample sizes too small to address this issue, but it can
be studied in joint efforts of prospective cohort studies start-
ing from early life onwards.1,17
The potential of collaborative efforts between large-scale
prospective cohort studies has been demonstrated by the
success of recent genome-wide association studies (GWAS)
which have shed light on the genetic background of com-
mon diseases as well as their risk factors. These GWAS are
characterized by state-of-the-art genome-wide agnostic
approaches in which millions of genetic variants are related
to a particular health outcome, usually in the setting of large
consortia combining the results of multiple studies, using
meta-analysis. Common genetic variants have been identi-
fied that are related to birthweight, childhood obesity, re-
spiratory phenotypes, atopic dermatitis and behavioural
outcomes among others.18–25 In line with these approaches,
recent developments enable analysis of hundreds of thou-
sands of DNA methylation markers across the genome on a
single array.26,27 The high-throughput and cost-effective na-
ture of these arrays has made it possible for studies to meas-
ure DNA methylation across the genome (‘epigenome-wide
DNA methylation’) in relatively large samples sizes. These
data can be used in epigenome-wide association studies
(EWAS) to evaluate associations of DNA methylation at
specific sites or regions of the genome with determinants
and outcomes of health and disease. EWAS in pregnancy,
birth or child cohorts specifically enable exploration of asso-
ciations of early life exposures with DNA methylation levels
in children, and of DNA methylation levels with specific
growth, development and health outcomes. Recent study-
specific EWAS have shown associations of DNA methyla-
tion levels in offspring with birthweight, maternal body
mass index and maternal smoking.28–31 Large sample sizes
are required to achieve optimal power in analyses of so
many genomic sites, especially if the prevalence of the ex-
posure or outcome under study is low. Collaboration be-
tween studies and combined meta-analysis of the available
data are needed to optimize the use of resources and to in-
crease the likelihood of detecting DNA methylation differ-
ences underlying the associations of early life exposures and
health outcomes.
This paper describes the global Pregnancy And
Childhood Epigenetics (PACE) Consortium which, to date,
brings together 39 studies with over 29 000 samples and
DNA methylation data in pregnant women, newborns
and/or children. Besides strongly increased power to detect
associations, bringing studies together in the PACE
Consortium for meta-analysis greatly decreases the risk of
false-positive associations. The larger power also enables
more detailed studies into potential causal roles of methy-
lation, using a mendelian randomization approach for
which large sample sizes are typically needed. In addition,
a number of studies have measured DNA methylation at
multiple time points from birth through childhood and/or
in adolescence, which enables investigation into the persist-
ence of differential DNA methylation signals over time.
Also, the availability of information from studies with par-
ticipants from various backgrounds in terms of ethnicity,
location and living environment enables testing of identi-
fied associations across different settings and evaluation of
heterogeneity of effects across study populations.
The primary aim of the PACE Consortium is to identify
differences in DNA methylation in relation to a wide range
of exposures and outcomes pertinent to health in preg-
nancy and childhood through joint analysis of DNA
methylation data. Secondary aims of the Consortium are
to perform further functional annotation-based analyses,
to attempt to assess causality of DNA methylation differ-
ences for child health phenotypes, to contribute to meth-
odological development and to exchange knowledge and
skills.
Who is in the Consortium?
In June 2013, an international group of studies focused on
maternal and child health met at the U.S. National
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Institute of Environmental Health Sciences to organize an
EWAS meta-analysis on maternal smoking in pregnancy
and DNA methylation in newborns and children.32 This
marked the start of the PACE Consortium. The success of
this initial effort resulted in the expansion of the
Consortium and inclusion of additional research groups, to
include additional exposures and outcomes. The PACE
Consortium is modelled after successful GWAS consortia,
in which many PACE investigators already participated,
including the Early Growth Genetics (EGG) Consortium,
the Early Genetics and Lifecourse Epidemiology (EAGLE)
Consortium and the Cohorts for Heart and Aging
Research in Genomic Epidemiology (CHARGE)
Consortium.33 Currently, the PACE Consortium includes
39 studies with genome-wide DNA methylation data from
pregnancy, newborn or childhood samples and informa-
tion on at least one of the exposures or outcomes of inter-
est. A list of studies currently involved in the PACE
Consortium with basic study information is shown in
Table 1. More detailed descriptions of the individual co-
horts can be found in the Supplementary material and
Supplementary Table 1, available at IJE online. The PACE
Consortium is an open, dynamic collaboration and add-
itional research groups are welcome to join.
The Consortium structure is purposefully kept simple.
The work in the Consortium is strongly researcher-
driven. Any member can propose an analysis. Projects are
often co-led by two or more researchers from different
studies. This supports collaboration and exchange of
knowledge and skills for both junior and senior re-
searchers. On most projects, junior researchers, often PhD
students or postdoctoral students, take the lead under the
supervision of a more experienced, senior researcher from
their own or another participating institution. The lead group
operates as the meta-analysis centre for a specific project. For
each project, a working group is formed and studies can opt
into or opt out of that specific project. Analyses are per-
formed according to a predefined analysis plan, which con-
tains inclusion and exclusion criteria, phenotype definitions,
covariates and statistical models, usually logistic or robust lin-
ear regression models. Each cohort performs its own quality
control and normalization of the EWAS data. We have
shown a very limited influence of different normalization
methods between cohorts on the results of EWAS meta-ana-
lyses.32 Each cohort analyses its own data according to the
analysis plan, after which the summary results are shared
with the meta-analysis centre. Data exchange is organized for
each project separately, usually through secure university-
based upload servers. These summary results include the ef-
fect estimate, standard error, P-value and included sample
size for each CpG analysed. In general, meta-analysis of sum-
mary results is the preferred approach and no individual-level
data are shared between the centres. However, integrated
data approaches may be considered, conditional on ethical
and legal agreements, which may differ for each individual
study; but such approaches have not been used so far.
Subsequently, the meta-analysis centre performs quality con-
trol of the summary results files and meta-analyses all data-
sets, with specific ‘omics’ meta-analysis software, such as
Metal.34 Standard quality controls include inspection of the
distribution of effect estimates and standard errors across co-
horts, and Manhattan plots of individual cohort and meta-
analysis results. The full process of quality control and meta-
analysis is independently repeated by an analyst from one of
the other participating studies (the ‘second centre’) as a qual-
ity control measure.
As a general rule, as many studies as possible are
included in the discovery meta-analysis to increase power to
discover new associated DNA methylation sites. Replication
of findings is then pursued in further studies that were un-
able to participate in the discovery meta-analysis, if avail-
able. After the discovery meta-analysis is finished, further
work is done in terms of validation and interpretation of the
results, including enrichment/pathway/functional network
analyses using publicly available resources, and
methylation-expression analyses (Figure 2). Often, such
follow-up work involves a look-up of the main findings in
children of different ages than in the main analysis. For ex-
ample, after a discovery analysis in cord blood samples, a
look-up of the findings in childhood and adolescent samples
may be done to study persistence of the identified signals.
Analyses in the PACE Consortium are performed col-
laboratively by the participating centres. Logistics are
organized by the National Institute of Environmental
Health Sciences in Research Triangle Park, NC, USA. All
ongoing and proposed analyses are discussed in bi-weekly
conference calls, during which project leaders give updates.
In addition, individual analysis groups may have separate
conference calls if needed.
How often have they been followed-up?
The PACE Consortium brings together a large number of co-
horts, each of them with cohort-specific protocols (Table 1,
Supplementary Table 1). Most studies have ongoing data col-
lection and follow-up. Many of the cohorts have multiple
follow-up time points from fetal life into childhood, and sev-
eral have follow-up into adolescence or early adulthood.
Most have information on maternal exposures during preg-
nancy, including maternal smoking and body mass
index.31,32 A number of studies also collected information on
more specific exposures, such as air pollution.35 All cohorts
have collected information on child physical and/or mental
development. Some studies have a particular focus, such as
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cleft lip and palate (NCL) or autism (SEED I), but most are
population-based cohorts collecting a vast amount of data on
many domains. These include anthropometric, cardiometa-
bolic, neurodevelopmental and respiratory measurements, as
well as childhood diseases. Further details of data collection
waves, follow-up and biological sample collection in all stud-
ies can be found in Supplementary Table 1. The PACE
Consortium is focused around the common methylation plat-
form. Studies commit to the PACE Consortium on a project-
by-project basis. They are not necessarily involved in PACE
with all their data, but rather decide per project whether or
not they will participate. It is therefore possible that a particu-
lar study is not involved in a PACE project on a specific topic,
for example because they decide to pursue a single-study pro-
ject or because they are involved in another collaboration on
that topic. In such cases, studies opt out of the project and
are not involved until the work is published. With ongoing
sample collection and data expansion in each study, increased
DNA methylation and phenotype measures will be available
in the future. Multiple cohorts have longitudinal measure-
ments of DNA methylation, and investigations on the persist-
ence of DNA methylation signals are possible. Repeated
measurements of outcomes during childhood, adolescence
and beyond will enable specific developmental or life course
trajectory analyses in relation to DNA methylation signals.
Study-specific details are described in the Supplementary ma-
terial and Supplementary Table 1.
What has been measured?
All studies involved in the PACE Consortium have com-
mon measures of DNA methylation. Currently the plat-
form used by the group is the Illumina 450 K
HumanMethylation array, the most widely used array in
large-scale human studies (Illumina Inc., San Diego,
USA).26 Recently a larger, compatible array (850 K EPIC)
was developed.27 New studies using this array can be
included in the Consortium in the future. The 450 K array
includes around 485 000 DNA methylation sites, covering
less than 2% of all sites across the genome. It is targeted at
genes and CpG islands, and sites were chosen based on ad-
vice of an international group of DNA methylation ex-
perts.26 The PACE Consortium currently focuses on
exposures occurring during pregnancy and childhood
health outcomes. Across studies, a vast number of expos-
ures and outcomes are available and studies usually partici-
pate in multiple analyses. The main exposures that the
PACE Consortium currently focuses on are those occurring
during pregnancy; the main outcomes are childhood health
parameters and diseases. An overview is given in Figure 3.
Recently, working groups have formed around methodo-
logical issues, such as blood cell composition adjustment
and evaluation of methods for identifying differentially
methylated regions. Many of the studies involved in the
PACE Consortium also have GWAS data and other types
of ‘omics’ data, including transcriptomics and
Figure 2. Flow diagram of the analytical processes.
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metabolomics if available, creating the possibility for inte-
grative omics analyses. The availability of GWAS data en-
ables analyses of associations of genetic variants with
DNA methylation, as well as analyses to assess the poten-
tial influence of genetic variation on methylation variance,
the possible causal role of DNA methylation differences
using a two-step mendelian randomization approach, and
adjustment for genetic markers of ancestry.36–38
What has it found?
A number of the cohorts involved in the PACE Consortium
have published cohort-specific EWAS on various pheno-
types, including maternal smoking, maternal body mass
index, maternal stress and child birthweight and sex, pre-
dating PACE projects on these topics.28–31,39–43 Some stud-
ies have involved collaborations between a few of the
PACE cohorts.44–47 In addition, members of the PACE
Consortium have contributed to methodological develop-
ments in the field, such as evaluation of normalization
methods, aspects of study design, and analysis software de-
velopment.48–54 Multiple consortium projects are currently
being analysed or prepared. Here, we would like to high-
light the first three published reports.
The first large PACE Consortium meta-analysis re-
ported on the results of a meta-analysis on maternal smok-
ing in relation to cord blood DNA methylation.32 This
meta-analysis of EWAS was on sustained maternal
smoking during pregnancy in 13 cohorts, with a total of
6685 newborns. There were 6073 differentially methylated
CpG sites in relation to maternal smoking during preg-
nancy, after multiple testing correction using a false discov-
ery rate of 5%, of which half had not previously been
identified for their association with either maternal smok-
ing during pregnancy or smoking in adults. This analysis
showed the increased power leveraged by large consortium
analysis. Analyses of older children (five cohorts,
N¼ 3187) indicated that most of these DNA methylation
signals observed at birth persist into childhood, but are
attenuated. A number of the differentially methylated CpG
sites were in or near genes with known roles in diseases
associated with maternal smoking, such as orofacial clefts
and asthma. We also found enrichment in developmental
processes.
The second report was a meta-analysis of the associ-
ation of maternal plasma folate levels during pregnancy
among 1988 newborns from two cohorts. Differential
methylation of 443 CpG sites related to 320 genes was
found, with most of these genes having no known function
in folate biology.44
The third, most recent meta-analysis reported the re-
sults of an assessment of the association of prenatal air pol-
lution exposure and cord blood DNA methylation in four
cohorts, spanning 1508 participants.55 It showed that ex-
posure to nitrogen dioxide during pregnancy was associ-
ated with differential offspring DNA methylation in
Figure 3. Current main exposures, outcomes and methodological topics in the PACE Consortium.
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mitochondria-related genes, as well as in several genes
involved in antioxidant defence pathways. Some of these
associations also persisted to older ages.55 A current over-
view of published papers from the PACE Consortium can
be found at: [http://www.niehs.nih.gov/research/atniehs/
labs/epi/pi/genetics/pace/index.cfm].
What are the main strengths and
weaknesses?
Main strengths
Although individual-cohort analyses can reveal associated
DNA methylation sites, joining forces in meta-analyses
within a consortium brings significant benefits. First, it
substantially increases sample size, facilitating the discov-
ery of novel loci and optimizing the use of resources.
Second, it offers the potential for analyses of DNA methy-
lation signals at various ages throughout infancy, child-
hood and adolescence. Third, this setting makes it possible
to compare effects between different populations and eth-
nicities. Fourth, a consortium setting allows replication of
findings across studies, thus decreasing the publication of
false-positive results from individual studies. Fifth, EWAS
analyses in pregnancy, birth and child cohort studies offer
an enormous potential to shed light on mechanisms under-
lying the associations of early, fetal and childhood expos-
ures with later life health and disease, and on a potential
role of DNA methylation as a biomarker of exposures or
outcomes. The longitudinal data collection from early life
onwards enables us to study the role of DNA methylation
in life course health trajectories. Sixth, the experience and
diverse backgrounds of the PACE investigators, including
epidemiologists, statisticians, geneticists, clinicians, bioin-
formaticians and biologists, enables sharing of methods
and analytical code, quicker solutions to methodological
issues and easier exchange of knowledge and skills. The ex-
perience of many PACE investigators in existing consortia,
often with the same partner studies, was of great benefit at
the start of the PACE Consortium. Issues that may have
posed challenges to earlier consortia, such as communica-
tion between studies, harmonizing analytical methods, and
authorship strategies, were hence part of the ‘basic skill
set’ of this Consortium.33 Seventh, the Consortium also
offers outstanding networking opportunities for students,
postdocs and junior investigators in their career develop-
ment. Based on recent experience in GWAS consortia, we
expect that the PACE structure can be a springboard for
both junior and senior investigators to apply for funding
for new projects, including those that require additional
analyses of samples, exposures or outcomes. Similar to
many other consortia, the PACE Consortium has no
structural or central funding other than the modest admin-
istrative support from the National Institute of
Environmental Health Sciences for conference calls, the
website and the three in-person meetings held to date.
Main weaknesses
Analyses of epigenome-wide DNA methylation face par-
ticular methodological challenges. First, the analyses in the
PACE Consortium are mainly performed on DNA ex-
tracted from blood samples, which are easily collected in
population-based settings. However, each cell type may
have its own unique methylation profile. Thus, DNA
methylation in leukocytes does not necessarily represent
DNA methylation in other tissues that may be more rele-
vant for certain phenotypes, for example lung tissue when
studying the association of DNA methylation and asthma.
This feature of DNA methylation studies in blood poses a
challenge in the interpretation of the findings. As cohort
studies involving young children will generally not be able
to collect more specific tissue samples, with the exception
of buccal cells, collaborations will be sought with other
partners in the future to be able to address tissue specifi-
city. A subset of PACE cohorts have DNA methylation
measured in placenta. Second, the distribution of blood
cell subtypes in blood samples varies in response to a range
of internal and external factors, such as infection, diseases
and smoking. As DNA methylation is cell-type specific, an
observed association of an exposure or an outcome with
DNA methylation may be the result of changes in blood
cell composition, rather than a representation of a true as-
sociation. Adjustment for blood cell composition in studies
using cord blood data is a challenge. So far, we have used
the regression calibration method of Houseman and col-
leagues, which until recently has been constrained to the
first available reference panel of 450 K data in white blood
cell subtypes of six adult males. This panel has been shown
to be suboptimal in estimating blood cell proportions in
DNA from newborns.49,56,57 Recently, PACE consortium
investigators reported on cord blood-specific methods for
blood cell composition correction.49,58,59 Third, as in any
epidemiological study, but less problematic in GWAS, con-
founding factors need to be taken into account in the ana-
lyses. In addition, confounding by technical covariates, or
batch effects, which has minimal effect on genotype calling
in GWAS, needs to be addressed in EWAS and may require
extensive adjustment. Given the size of the Consortium
and the number of studies that may be involved in a meta-
analysis, it can also be a challenge in terms of logistics and
time to ask individual studies to go back and re-run ana-
lyses with additional covariates or stratified on a particular
factor such as sex to study associations in more detail.
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Fourth, as certain outcomes or disease states may also
influence DNA methylation, the potential for reverse caus-
ality needs to be taken into account, especially in cross-
sectional analyses. Yet, even if a disease causes differences
in DNA methylation, these may still serve a clinical pur-
pose as biomarker of the disease or its progression.15 Such
epigenetic biomarkers may be used in disease prediction, as
a diagnostic test, in determining specific disease subtypes
or in informing on prognosis.3 Fifth, the currently used
DNA methylation arrays only cover 2–3% of the total
number of DNA methylation sites, with a focus on genes
and CpG islands.26,27 Even though the newer EPIC array
increases coverage of enhancer regions, the coverage will
still be relatively limited.27 Sixth, the integration of DNA
methylation data with other ‘omics’ data to gain insight
into their interrelations will also pose challenges, both in
terms of methodology and in terms of bioinformatics
approaches. An in-depth discussion of these methodo-
logical challenges is beyond the scope of this article, but
these are topics of ongoing work within and outside the
PACE Consortium.50,60–63 Seventh, the studies currently
involved in the PACE Consortium are located in industrial-
ized countries. Studying environmental exposures in low-
and middle-income settings would be relevant for a more
complete understanding of epigenetic mechanisms. As
PACE is an open consortium, we hope to be able to include
studies from developing countries in the future.
There is much to learn in the field of EWAS. The efforts
by this Consortium and many other researchers represent the
first steps in the discovery of the role of DNA methylation in
health and disease. Results from EWAS meta-analyses do not
stand on their own. Discovery results from EWAs need to be
followed by investigation of the relationships between DNA
methylation and gene expression, of the roles of biological
pathways on outcomes and of causality between exposures
and DNA methylation. Conversely, results from laboratory
scientists may inspire new analyses of DNA methylation in
human studies. Many methodological issues need to be
resolved. The PACE Consortium offers a strong platform to
address these points and to contribute to the field of popula-
tion epigenetics in the future.
Can I get hold of the data? Where can I find
out more?
The PACE Consortium is an open consortium and studies
interested in participating in one or more analyses are wel-
come to join. Each individual cohort analyses its own data
locally and only summary statistics, including cohort-
specific effect estimates, standard errors and P-values for
each CpG site, are shared for the meta-analysis. Therefore,
for access to data from individual cohorts in the PACE
Consortium, researchers should contact studies directly.
Study-specific protocols can be found through the study
websites (Supplementary material and Supplementary
Table 1) or through contact with study investigators.
Researchers interested in participating in the PACE
Consortium can contact the corresponding authors of this
paper. Meta-analysis summary statistics will be made pub-
licly available, in accordance with journal requirements.
For more information, please see: [http://www.niehs.nih.
gov/research/atniehs/labs/epi/pi/genetics/pace/index.cfm].
Supplementary Data
Supplementary data are available at IJE online.
Profile in a nutshell
• The PACE Consortium is an open consortium that
brings together studies with epigenome-wide DNA
methylation data in pregnant women, newborns
and/or children, with the aim to identify, using meta-
analysis, differences in DNA methylation in associa-
tion with a wide range of exposures and outcomes
related to health across the life course.
• Currently, the consortium includes 39 studies with over
29 000 samples with epigenome-wide DNA methyla-
tion data. Participation is on a project-by-project basis.
• Projects to date include gestational exposures and
maternal behaviours, such as maternal alcohol use,
body mass index, gestational weight gain, stress,
diet, air pollution, maternal diseases and smoking.
Outcomes under study include childhood growth
and obesity, and cardiometabolic, neurodevelop-
mental, respiratory and allergic phenotypes.
• Researchers interested in participating can contact the
corresponding authors (J.F.F. and S.J.L.) of this paper.
For more information: [http://www.niehs.nih.gov/
research/atniehs/labs/epi/pi/genetics/pace/index.cfm].
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